Plea To Lower Age For Mammography Screening In The UK (p 246)July 16, 2003Two leading UK cancer experts are calling for the entry age for mammographic screening for breast cancer to be reduced from 50 to 47 years for women in the UK. Their rationale is detailed in a correspondence letter in this week's issue of THE LANCET. Screening mammography became widely available from the UK National Health Service in the late 1980s. Women aged 50-64 years are invited for screening every three years. Considerable debate surrounds the ideal age for women to enter screening programmes; an ongoing trial due to report at the end of 2004 could recommend lowering the entry age to women in their 40s. Peter Sasieni and Jack Cuzick (both leading scientists at Cancer Research UK) believe there is sufficient evidence now to lower the entry age for screening ahead of the ongoing research. Peter Sasieni comments: "At age 40 years, the annual rate of breast cancer is 79 per 100 000 women, but rises substantially to 148 per 100 000 women at age 47 years and 152 per 100 000 women at age 48 years. Between age 48 and 54 years, the rates of breast cancer plateau before again increasing more slowly reaching 221 per 100 000 women by age 64 years. Thus, the incidence rate of breast cancer at age 48-49 years is as great as that at age 50-54 years, and the number of life-years that could be saved is potentially greater among these younger women." Jack Cuzick adds: "Although it is justifiable not to screen women in their early 40s without additional evidence, the case for offering screening to women aged 47 years is as strong as the case for offering screening to women aged 50 years. Starting mammographic screening at age 47 years, rather than at age 48 years, allows for a 1 year lead-time for screen-detected cancers. We propose that it is time to begin screening at age 47 years in all women, with screening every 3 years thereafter." Lancet |
|||||||||||||||||||||
| Related Breast Cancer Current Events and Breast Cancer News Articles Menopause-cardiology consensus statement on cardiovascular disease and on HRT A menopause-cardiology consensus statement has called for direct action to prevent cardiovascular disease (CVD) in menopausal women. The statement also concludes that there is little evidence of increased CVD risk in taking HRT. Researchers Identify Role of Gene in Tumor Development, Growth and Progression Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine researchers have identified a gene that may play a pivotal role in two processes that are essential for tumor development, growth and progression to metastasis. UCLA researchers create 'fly paper' to capture circulating cancer cells Just as fly paper captures insects, an innovative new device with nano-sized features developed by researchers at UCLA is able to grab cancer cells in the blood that have broken off from a tumor. Fertility procedures need not delay breast cancer treatment for younger women A new study published in the November issue of the Journal of the American College of Surgeons shows that breast cancer patients under 40 years old who undergo fertility preservation do not face a significant delay in the treatment of their disease when their care is coordinated in a timely fashion. Coffee break: Compound brewing new research in colon, breast cancer A compound in coffee has been found to be estrogenic in studies by Texas AgriLife Research scientists. Drugs to treat anemia in cancer patients linked to thromboembolism Medications frequently given to cancer patients to reduce their risk of anemia are associated with an increased risk of deep vein thrombosis or pulmonary embolism, according to new research led by Dawn Hershman, M.D, M.S., co-director of the breast cancer program at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital/Columbia University Medical Center. Discovery in worms by Queen's researchers points to more targeted cancer treatment Researchers at Queen's University have found a link between two genes involved in cancer formation in humans, by examining the genes in worms. The groundbreaking discovery provides a foundation for how tumor-forming genes interact, and may offer a drug target for cancer treatment. FDA approved leukemia drugs shows promise in ovarian cancer cells The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found. Carnegie Mellon researchers link health-care debate to risk of dying in US and Europe The current health care debate in the United States is complicated. Trade-offs between heath care expenditures, lifestyle choices and life expectancy have been suggested but seldom clearly demonstrated. Scientists uncover new key to the puzzle of hormone therapy and breast cancer The use of postmenopausal hormone therapy has decreased over time in the United States, which researchers suggest may play a key role in the declining rate of atypical ductal hyperplasia, a known risk factor for breast cancer. More Breast Cancer Current Events and Breast Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||